CBER Director Peter Marks (Susan Walsh/AP Images)
February 15, 2023 12:11 PM ESTUpdated February 16, 06:37 AM
Pharma
Cell/Gene Tx
FDA+
In Focus

Thou­sands of gene and cell ther­a­pies are in­un­dat­ing FDA re­view­ers as the agency tries to keep up

Zachary Brennan

Senior Editor

The FDA’s staff is flood­ed with thou­sands of cell and gene ther­a­py tri­als mak­ing their way through a short-hand­ed reg­u­la­to­ry work­force.

While the FDA has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times